NCT06726564View on ClinicalTrials.gov

A Study of MT027 in Patients with Pleural Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

February 28, 2029

Conditions
Advanced Malignant Solid TumorMalignant Pleural EffusionPleura CarcinomaPleural MesotheliomaPleural Malignant MesotheliomaPleural Metastases
Interventions
DRUG

MT027 cells suspension

MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Suzhou Maximum Bio-tech Co., Ltd.

INDUSTRY